Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy

[1]  J. Pandy,et al.  Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review , 2019, BMC Cancer.

[2]  Z. Varga,et al.  Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018 , 2019, Journal of Cancer Research and Clinical Oncology.

[3]  P. Fasching,et al.  Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus , 2019, Geburtshilfe und Frauenheilkunde.

[4]  A. Kiss,et al.  Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis , 2019, BMC Cancer.

[5]  J. Lee,et al.  A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients , 2018, Breast Cancer Research and Treatment.

[6]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Ceppi,et al.  Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Mike Clarke,et al.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.

[9]  M. Espié,et al.  Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. , 2017, European journal of cancer.

[10]  G. Tozbikian,et al.  Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management? , 2017, Human pathology.

[11]  A. Noske,et al.  Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience , 2015, PloS one.

[12]  A. Sapino,et al.  The Perfect Pathology Report After Neoadjuvant Therapy. , 2015, Journal of the National Cancer Institute. Monographs.

[13]  M. Untch,et al.  Current and future role of neoadjuvant therapy for breast cancer. , 2014, Breast.

[14]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[15]  J Bogaerts,et al.  Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Barni,et al.  The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.

[17]  Holger Moch,et al.  Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study , 2013, BMC Cancer.

[18]  Carsten Denkert,et al.  Response-guided neoadjuvant chemotherapy for breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[20]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Jabbour,et al.  Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma , 2012, Breast Cancer Research and Treatment.

[22]  Ning Zhang,et al.  The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-Analysis , 2011, Cancer investigation.

[23]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  T. Fehm,et al.  HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. , 2009, Anticancer research.

[25]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[26]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[27]  T. Uematsu,et al.  Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. , 2008, Breast.

[28]  J. A. van der Hage,et al.  Preoperative chemotherapy for women with operable breast cancer. , 2007, The Cochrane database of systematic reviews.

[29]  Z. Varga,et al.  Stability of the HER2 gene after primary chemotherapy in advanced breast cancer , 2005, Virchows Archiv.

[30]  M. Gnant,et al.  Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer , 2003, Breast Cancer Research and Treatment.

[31]  M. J. van de Vijver,et al.  Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.

[32]  R. K. Knight,et al.  Combined chemotherapy and radiotherapy for locally advanced breast cancer. , 1980, European journal of cancer.